<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35243403</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2666-3287</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>7</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>JAAD international</Title>
          <ISOAbbreviation>JAAD Int</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cutaneous findings in myotonic dystrophy.</ArticleTitle>
        <Pagination>
          <StartPage>7</StartPage>
          <EndPage>12</EndPage>
          <MedlinePgn>7-12</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jdin.2021.09.008</ELocationID>
        <Abstract>
          <AbstractText>Myotonic dystrophy types 1 and 2 are a group of complex genetic disorders resulting from the expansion of (CTG)<sub>n</sub> nucleotide repeats in the <i>DMPK</i> gene. In addition to the hallmark manifestations of myotonia and skeletal muscle atrophy, myotonic dystrophy also affects a myriad of other organs including the heart, lungs, as well as the skin. The most common cutaneous manifestations of myotonic dystrophy are early male frontal alopecia and adult-onset pilomatricomas. Myotonic dystrophy also increases the risk of developing malignant skin diseases such as basal cell carcinoma and melanoma. To aid in the diagnosis and treatment of myotonic dystrophy related skin conditions, it is important for the dermatologist to become cognizant of the common and rare cutaneous manifestations of this genetic disorder. We performed a PubMed search using the key terms "myotonic dystrophy" AND "cutaneous" OR "skin" OR "dermatologic" AND "manifestation" OR "finding." The resulting publications were manually reviewed for additional relevant publications, and subsequent additional searches were performed as needed, especially regarding the molecular mechanisms of pathogenesis. In this review, we aim to provide an overview of myotonic dystrophy types 1 and 2 and summarize their cutaneous manifestations as well as potential mechanisms of pathogenesis.</AbstractText>
          <CopyrightInformation>© 2021 Published by Elsevier Inc on behalf of the American Academy of Dermatology, Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kong</LastName>
            <ForeName>Ha Eun</ForeName>
            <Initials>HE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pollack</LastName>
            <ForeName>Brian P</ForeName>
            <Initials>BP</Initials>
            <AffiliationInfo>
              <Affiliation>Atlanta VA Health System, Decatur, Georgia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Winship Cancer Institute of Emory University School of Medicine, Atlanta, Georgia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>JAAD Int</MedlineTA>
        <NlmUniqueID>101774762</NlmUniqueID>
        <ISSNLinking>2666-3287</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">BCC</Keyword>
        <Keyword MajorTopicYN="N">BCC, basal cell carcinoma</Keyword>
        <Keyword MajorTopicYN="N">DM1</Keyword>
        <Keyword MajorTopicYN="N">DM1, myotonic dystrophy type 1</Keyword>
        <Keyword MajorTopicYN="N">DM2</Keyword>
        <Keyword MajorTopicYN="N">DM2, myotonic dystrophy type 2</Keyword>
        <Keyword MajorTopicYN="N">DMPK, myotonic dystrophy protein kinase</Keyword>
        <Keyword MajorTopicYN="N">RAN, repeat associated non-ATG</Keyword>
        <Keyword MajorTopicYN="N">RNA toxicity</Keyword>
        <Keyword MajorTopicYN="N">melanoma</Keyword>
        <Keyword MajorTopicYN="N">myotonic dystrophy</Keyword>
        <Keyword MajorTopicYN="N">pilomatricoma</Keyword>
        <Keyword MajorTopicYN="N">syndrome</Keyword>
        <Keyword MajorTopicYN="N">triplet repeat expansion</Keyword>
      </KeywordList>
      <CoiStatement>None disclosed.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>5</Hour>
          <Minute>44</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35243403</ArticleId>
        <ArticleId IdType="pmc">PMC8867117</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jdin.2021.09.008</ArticleId>
        <ArticleId IdType="pii">S2666-3287(21)00077-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Johnson N.E., Heatwole C.R. Myotonic dystrophy: from bench to bedside. Semin Neurol. 2012;32(3):246–254. doi: 10.1055/s-0032-1329202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0032-1329202</ArticleId>
            <ArticleId IdType="pubmed">23117949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thornton C.A. Myotonic dystrophy. Neurol Clin. 2014;32(3):705–719. doi: 10.1016/j.ncl.2014.04.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ncl.2014.04.011</ArticleId>
            <ArticleId IdType="pmc">PMC4105852</ArticleId>
            <ArticleId IdType="pubmed">25037086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Day J.W., Ricker K., Jacobsen J.F., et al.  Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology. 2003;60(4):657–664. doi: 10.1212/01.WNL.0000054481.84978.F9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000054481.84978.F9</ArticleId>
            <ArticleId IdType="pubmed">12601109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brook J.D., McCurrach M.E., Harley H.G., et al.  Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell. 1992;68(4):799–808. doi: 10.1016/0092-8674(92)90154-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0092-8674(92)90154-5</ArticleId>
            <ArticleId IdType="pubmed">1310900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahadevan M., Tsilfidis C., Sabourin L., et al.  Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science. 1992;255(5049):1253–1255. doi: 10.1126/science.1546325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1546325</ArticleId>
            <ArticleId IdType="pubmed">1546325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu Y., Pizzuti A., Fenwick R., et al.  An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science. 1992;255(5049):1256–1258. doi: 10.1126/science.1546326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1546326</ArticleId>
            <ArticleId IdType="pubmed">1546326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liquori C.L., Ricker K., Moseley M.L., et al.  Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science. 2001;293(5531):864–867. doi: 10.1126/science.1062125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1062125</ArticleId>
            <ArticleId IdType="pubmed">11486088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meola G., Cardani R. Myotonic dystrophies: an update on clinical aspects, genetic, pathology, and molecular pathomechanisms. Biochim Biophys Acta. 2015;1852(4):594–606. doi: 10.1016/j.bbadis.2014.05.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2014.05.019</ArticleId>
            <ArticleId IdType="pubmed">24882752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hunter A., Tsilfidis C., Mettler G., et al.  The correlation of age of onset with CTG trinucleotide repeat amplification in myotonic dystrophy. J Med Genet. 1992;29(11):774–779. doi: 10.1136/jmg.29.11.774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jmg.29.11.774</ArticleId>
            <ArticleId IdType="pmc">PMC1016169</ArticleId>
            <ArticleId IdType="pubmed">1453425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsilfidis C., MacKenzie A.E., Mettler G., Barceló J., Korneluk R.G. Correlation between CTG trinucleotide repeat length and frequency of severe congenital myotonic dystrophy. Nat Genet. 1992;1(3):192–195. doi: 10.1038/ng0692-192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng0692-192</ArticleId>
            <ArticleId IdType="pubmed">1303233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meola G. Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies. Acta Myol. 2013;32(3):154–165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4006279</ArticleId>
            <ArticleId IdType="pubmed">24803843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashizawa T., Dubel J.R., Dunne P.W., et al.  Anticipation in myotonic dystrophy. II. Complex relationships between clinical findings and structure of the GCT repeat. Neurology. 1992;42(10):1877–1883. doi: 10.1212/wnl.42.10.1877.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/wnl.42.10.1877</ArticleId>
            <ArticleId IdType="pubmed">1407566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Timchenko L. Molecular mechanisms of muscle atrophy in myotonic dystrophies. Int J Biochem Cell Biol. 2013;45(10):2280–2287. doi: 10.1016/j.biocel.2013.06.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biocel.2013.06.010</ArticleId>
            <ArticleId IdType="pmc">PMC3759660</ArticleId>
            <ArticleId IdType="pubmed">23796888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Philips A.V., Timchenko L.T., Cooper T.A. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science. 1998;280(5364):737–741. doi: 10.1126/SCIENCE.280.5364.737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/SCIENCE.280.5364.737</ArticleId>
            <ArticleId IdType="pubmed">9563950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller J.W., Urbinati C.R., Teng-Umnuay P., et al.  Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J. 2000;19(17):4439–4448. doi: 10.1093/EMBOJ/19.17.4439.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/EMBOJ/19.17.4439</ArticleId>
            <ArticleId IdType="pmc">PMC302046</ArticleId>
            <ArticleId IdType="pubmed">10970838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osborne R.J., Thornton C.A. RNA-dominant diseases. Hum Mol Genet. 2006;15(Spec No 2):R162–R169. doi: 10.1093/HMG/DDL181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/HMG/DDL181</ArticleId>
            <ArticleId IdType="pubmed">16987879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taneja K.L., McCurrach M., Schalling M., Housman D., Singer R.H. Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J Cell Biol. 1995;128(6):995–1002. doi: 10.1083/jcb.128.6.995.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.128.6.995</ArticleId>
            <ArticleId IdType="pmc">PMC2120416</ArticleId>
            <ArticleId IdType="pubmed">7896884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Timchenko L.T., Miller J.W., Timchenko N.A., et al.  Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy. Nucleic Acids Res. 1996;24(22):4407–4414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC146274</ArticleId>
            <ArticleId IdType="pubmed">8948631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Timchenko L.T., Timchenko N.A., Caskey C.T., Roberts R. Novel proteins with binding specificity for DNA CTG repeats and RNA CUG repeats: implications for myotonic dystrophy. Hum Mol Genet. 1996;5(1):115–121. doi: 10.1093/hmg/5.1.115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/5.1.115</ArticleId>
            <ArticleId IdType="pubmed">8789448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Timchenko N.A., Cai Z.-J., Welm A.L., Reddy S., Ashizawa T., Timchenko L.T. RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem. 2001;276(11):7820–7826. doi: 10.1074/jbc.M005960200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M005960200</ArticleId>
            <ArticleId IdType="pubmed">11124939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Timchenko N.A., Patel R., Iakova P., Cai Z.-J., Quan L., Timchenko L.T. Overexpression of CUG triplet repeat-binding protein, CUGBP1, in mice inhibits myogenesis. J Biol Chem. 2004;279(13):13129–13139. doi: 10.1074/jbc.M312923200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M312923200</ArticleId>
            <ArticleId IdType="pubmed">14722059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zu T., Liu Y., Bañez-Coronel M., et al.  RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A. 2013;110(51):E4968–E4977. doi: 10.1073/pnas.1315438110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1315438110</ArticleId>
            <ArticleId IdType="pmc">PMC3870665</ArticleId>
            <ArticleId IdType="pubmed">24248382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zu T., Cleary J.D., Liu Y., et al.  RAN Translation regulated by muscleblind proteins in myotonic dystrophy type 2. Neuron. 2017;95(6):1292–1305.e5. doi: 10.1016/J.NEURON.2017.08.039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/J.NEURON.2017.08.039</ArticleId>
            <ArticleId IdType="pmc">PMC5951173</ArticleId>
            <ArticleId IdType="pubmed">28910618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mankodi A., Logigian E., Callahan L., et al.  Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science. 2000;289(5485):1769–1773. doi: 10.1126/science.289.5485.1769.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.289.5485.1769</ArticleId>
            <ArticleId IdType="pubmed">10976074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones K., Wei C., Iakova P., et al.  GSK3β mediates muscle pathology in myotonic dystrophy. J Clin Invest. 2012;122(12):4461–4472. doi: 10.1172/JCI64081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI64081</ArticleId>
            <ArticleId IdType="pmc">PMC3533547</ArticleId>
            <ArticleId IdType="pubmed">23160194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seznec H., Agbulut O., Sergeant N., et al.   Vol. 10. Oxford University Press; 2001.  (Mice Transgenic for the Human Myotonic Dystrophy Region with Expanded CTG Repeats Display Muscular and Brain Abnormalities).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11726559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geh J.L., Moss A.L. Multiple pilomatrixomata and myotonic dystrophy. A familial association. Br J Plast Surg. 1999;52(2):143–145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10434894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciriacks K., Knabel D., Waite M.B. Syndromes associated with multiple pilomatricomas: when should clinicians be concerned? Pediatr Dermatol. 2020;37(1):9–17. doi: 10.1111/pde.13947.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/pde.13947</ArticleId>
            <ArticleId IdType="pubmed">31618803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cantwell A.R., Reed W.B. Myotonia atrophica and multiple calcifying epithelioma of Malherbe. Acta Derm Venereol. 1965;45(5):387–390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4162862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mueller C.M., Hilbert J.E., Martens W., Thornton C.A., Moxley R.T., Greene M.H. Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control. 2009;20(10):2009–2020. doi: 10.1007/s10552-009-9395-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10552-009-9395-y</ArticleId>
            <ArticleId IdType="pmc">PMC3110730</ArticleId>
            <ArticleId IdType="pubmed">19642006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park J.H., Terushkin V., Brinster N., Leger M., Soter N.A. Multiple pilomatricomas in the setting of myotonic dystrophy. Dermatol Online J. 2016;22(12) 13030/qt2q9081v5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28329537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kentley J., Nasir S., Lloyd K., Markiewicz D., Harwood C.A. Multiple pilomatrixomas as a presentation of myotonic dystrophy. Clin Exp Dermatol. 2019;44(4):e149–e150. doi: 10.1111/ced.13946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ced.13946</ArticleId>
            <ArticleId IdType="pubmed">30734963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rübben A., Wahl R.U., Eggermann T., Dahl E., Ortiz-Brüchle N., Cacchi C. Mutation analysis of multiple pilomatricomas in a patient with myotonic dystrophy type 1 suggests a DM1-associated hypermutation phenotype. PLoS One. 2020;15(3):e0230003. doi: 10.1371/journal.pone.0230003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0230003</ArticleId>
            <ArticleId IdType="pmc">PMC7064234</ArticleId>
            <ArticleId IdType="pubmed">32155193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lazar A.J.F., Calonje E., Grayson W., et al.  Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding β-catenin. J Cutan Pathol. 2005;32(2):148–157. doi: 10.1111/j.0303-6987.2005.00267.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.0303-6987.2005.00267.x</ArticleId>
            <ArticleId IdType="pubmed">15606674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan E.F., Gat U., McNiff J.M., Fuchs E. A common human skin tumour is caused by activating mutations in β- catenin. Nat Genet. 1999;21(4):410–413. doi: 10.1038/7747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/7747</ArticleId>
            <ArticleId IdType="pubmed">10192393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moreno-Bueno G., Gamallo C., Pérez-Gallego L., Contreras F., Palacios J. β-catenin expression in pilomatrixomas. Relationship with β-catenin gene mutations and comparison with β-catenin expression in normal hair follicles. Br J Dermatol. 2001;145(4):576–581. doi: 10.1046/j.1365-2133.2001.04455.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2133.2001.04455.x</ArticleId>
            <ArticleId IdType="pubmed">11703283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campione E., Botta A., Di Prete M., et al.  Cutaneous features of myotonic dystrophy types 1 and 2: implication of premature aging and vitamin D homeostasis. Neuromuscul Disord. 2017;27(2):163–169. doi: 10.1016/j.nmd.2016.11.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2016.11.004</ArticleId>
            <ArticleId IdType="pubmed">28065683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Portaro S., Naro A., Guarneri C., Di Toro G., Manuli A., Calabrò R.S. Hemangiomas of the tongue and the oral cavity in a myotonic dystrophy type 1 patient: a case report. Medicine (Baltimore) 2018;97(48) doi: 10.1097/MD.0000000000013448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000013448</ArticleId>
            <ArticleId IdType="pmc">PMC6283126</ArticleId>
            <ArticleId IdType="pubmed">30508964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stieler W., Plewig G. Multiple basaliomas in Curschmann–Steinert myotonia atrophica. Article in German. Hautarzt. 1986;37:226–229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3700107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng J., Lachance A., Sinclair D.A., Asgari M.M. Multiple basal cell carcinomas in a patient with myotonic dystrophy type 1. BMJ Case Rep. 2019;12(3):e227233. doi: 10.1136/bcr-2018-227233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bcr-2018-227233</ArticleId>
            <ArticleId IdType="pmc">PMC6441996</ArticleId>
            <ArticleId IdType="pubmed">30852496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., Pfeiffer R.M., Alsaggaf R., et al.  Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the UK Clinical Practice Research Datalink. Int J Cancer. 2018;142(6):1174–1181. doi: 10.1002/ijc.31143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.31143</ArticleId>
            <ArticleId IdType="pmc">PMC5773358</ArticleId>
            <ArticleId IdType="pubmed">29114849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marcoval J., Olivé M., Bonfill-Ortí M., Martínez-Molina L., Talavera-Belmonte A. Cutaneous neoplasms in myotonic dystrophy type 1. Dermatology. 2016;232(6):700–703. doi: 10.1159/000456074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000456074</ArticleId>
            <ArticleId IdType="pubmed">28249295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Emparanza J.I., López de Munain A., Greene M.H., Matheu A., Fernández-Torrón R., Gadalla S.M. Cancer phenotype in myotonic dystrophy patients: results from a meta-analysis. Muscle Nerve. 2018;58(4):517–522. doi: 10.1002/mus.26194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.26194</ArticleId>
            <ArticleId IdType="pmc">PMC6173974</ArticleId>
            <ArticleId IdType="pubmed">30028904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alsaggaf R., St. George D.M.M., Zhan M., et al.  Cancer risk in myotonic dystrophy type I: evidence of a role for disease severity. JNCI Cancer Spectr. 2018;2(4):pky052. doi: 10.1093/jncics/pky052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jncics/pky052</ArticleId>
            <ArticleId IdType="pmc">PMC6286884</ArticleId>
            <ArticleId IdType="pubmed">30556050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bianchi M.L.E., Leoncini E., Masciullo M., et al.  Increased risk of tumor in DM1 is not related to exposure to common lifestyle risk factors. J Neurol. 2016;263(3):492–498. doi: 10.1007/s00415-015-8006-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-015-8006-y</ArticleId>
            <ArticleId IdType="pmc">PMC7814867</ArticleId>
            <ArticleId IdType="pubmed">26739382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alsaggaf R., Wang Y., Marini-Bettolo C., et al.  Benign and malignant tumors in the UK myotonic dystrophy patient registry. Muscle Nerve. 2018;57(2):316–320. doi: 10.1002/mus.25736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.25736</ArticleId>
            <ArticleId IdType="pmc">PMC7188193</ArticleId>
            <ArticleId IdType="pubmed">28662292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meta E., Imhof B.A., Ropraz P., et al.  The pyrazolyl-urea GeGe3 inhibits tumor angiogenesis and reveals dystrophia myotonica protein kinase (DMPK)1 as a novel angiogenesis target. Oncotarget. 2017;8(64):108195–108212. doi: 10.18632/oncotarget.22598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.22598</ArticleId>
            <ArticleId IdType="pmc">PMC5746136</ArticleId>
            <ArticleId IdType="pubmed">29296234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Itoh K., Ebata T., Hirata H., et al.  DMPK is a new candidate mediator of tumor suppressor p53-dependent cell death. Molecules. 2019;24(17) doi: 10.3390/molecules24173175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/molecules24173175</ArticleId>
            <ArticleId IdType="pmc">PMC6749264</ArticleId>
            <ArticleId IdType="pubmed">31480541</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
